Tenet Healthcare

Tenet Healthcare shares fell about 2.3% in premarket trading after board member Richard J. Mark sold 10,000 shares on September 10 at a weighted average price of roughly $263.42. The sale sparked selling pressure near recent highs, even though Tenet comfortably beat analyst expectations for Q2 2026 with adjusted earnings of $6.12 per share and revenue of $5.63 billion. After the partial sale, Mark still holds 25,121 shares, indicating no full exit. » Mere på de.investing.com

Tenet Healthcare presented a growth strategy at the Wells Fargo Healthcare Conference calling for increased investment, tighter cost control and a focus on highly complex procedures in hospitals and ambulatory surgery centers. Management raised the full‑year outlook, citing volume growth, an improved payer mix and cost discipline despite headwinds from Exchanges and Medicaid. The capex ratio was raised to about 5% of revenue, and Conifer is going through a transition year with expected efficiency gains in early 2025. AI spending remains selective and will be focused on use cases with clear returns such as OR planning and length‑of‑stay management. » Mere på de.investing.com

Tenet reported 52.2% adjusted EPS growth and 6.8% revenue growth, driven by a 9.3% rise in ambulatory revenue and hospital adjusted EBITDA margin expansion to 18%, signaling operating leverage across its hospital and ambulatory businesses. Risks include declining procedure volumes at its ambulatory platform and an unfavorable payer mix that could pressure future revenue quality. Medtronic's recovery is less advanced but supported by rapid growth in cardiac ablation and a diversified device pipeline that could deliver longer-term upside if broad adoption continues. » Mere på finance.yahoo.com

Tenet Healthcare posted net income of $826 million in the second quarter ($9.84 per diluted share) and adjusted earnings per share of $6.12 (+52.2%). Adjusted EBITDA rose to $1.3 billion, exceeding the top end of the company’s guidance. The board increased the share buyback program by $2 billion and raised the 2026 adjusted EBITDA guidance to $4.83–5.03 billion, while also boosting expected adjusted free cash flows; the stock has jumped significantly since the release (about +35.8% from the prior close). » Mere på finanzen.net

Tenet Healthcare shares rose to a record high of $270.79 and are up about 54.4% year-to-date. The P/E ratio is 10.46 and the PEG is 0.15, suggesting an attractive valuation relative to growth. Tenet beat expectations in Q2 2026 with adjusted earnings of $6.12 per share on revenue of $5.63 billion and subsequently raised its full-year guidance. Several analysts raised their price targets, including Guggenheim ($283), Raymond James ($275) and UBS ($308). » Mere på de.investing.com